Business
Innoviva to Participate in the Cantor Global Healthcare Conference
BURLINGAME, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other
About this update from Innoviva, Inc.
BURLINGAME, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Pavel Raifeld , Chief Executive Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference in New York, NY on Wednesday, September 27, 2023 at 1:50 p.m. Eastern Time . A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at https://investor.inva.com/presentations-events . The webcast will be available for replay for 90 days following the event. About Innoviva Innoviva, Inc. , is a diversified holding company with a portfolio of royalties and other healthcare assets, including Innoviva Specialty Therapeutics, a subsidiary focused on delivering innovative therapies in critical care and infectious disease. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/vilanterol, FF/VI) and ANORO® ELLIPTA® (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies. For more information on Innoviva , please visit here . View source version on businesswire.com : https://www.businesswire.com/news/home/20230919112391/en/ Investors & Media: Argot Partners (212) 600-1902 [email protected] Source: Innoviva, Inc.